EUnetHTA

The EUnetHTA 21 Consortium will cease operating on 16 September 2023. The HTA Regulation Secretariat at the European Commission will be the contact point for matters related to HTA collaboration under the HTAR.

The European Health and Digital Executive Agency signed the Service Contract for the Provision of Joint Health Technology Assessment Work Supporting the Continuation of EU Cooperation on HTA with the EUnetHTA 21 Consortium. The 24-month contract is due to expire on 16 September 2023, and the EUnetHTA 21 Consortium will cease operating as of this date.

On July 27, 2022, the EUnetHTA 21 released the assessment framework for high-risk medical devices (MDs) and in-vitro-diagnostics (IVDs). The objective of this deliverable is to define the framework for Joint Clinical Assessments of high-risk MDs and IVDs with a view to fostering national uptake of the Joint Clinical Assessments reports early in the life cycle of a single technology.

On 17 September 2021, the European Health and Digital Executive Agency signed the Service Contract for the Provision of Joint Health Technology Assessment Work Supporting the Continuation of EU Cooperation on HTA. The contract has now been awarded to the EUnetHTA21 consortium, which comprises the following 13 organizations from the EUnetHTA. The project will start in September 2021 and will run for two years (until September 2023).

At the beginning of August 2021, the European Network for Health Technology Assessment, EUnetHTA, released a final report on the surgical procedures for the treatment of obesity. The results suggest little or no difference in the effects of different bariatric surgery procedures on weight loss and diabetes control. However, the results are based mainly on low to very low certainty evidence, with few or even single studies providing data for many of the comparisons.

In late April 2021, the European Network for Health Technology Assessment, EUnetHTA, in partnership with the Austrian Institute for HTA (AIHTA), released a final report on the comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia. Twenty-one minimally invasive surgical treatments for benign prostatic hyperplasia were compared. Newer technologies may offer some advantage over transurethral resection of the prostate by reducing the transfusion requirement.

The Austrian Institute for Health Technology Assessment (AIHTA) completed a research project, “Lung cancer screening in risk groups: Systematic reviews of effectiveness and utility (part 1) and costs and budgetary consequences (part 2),” and published the reports in the mid of December 2020.

In August 2020, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA26 “Surgical procedures for treatment of obesity.” The key question of the assessment is bariatric surgery for the treatment of adults with obesity.

At the end of July 2020, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA27 “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH).”

In July 2020, the network of European HTA agencies, EUnetHTA, announced a final project plan of the project OTCA25 “Stereotactic Body Radiation Therapy (SBRT) for lung, prostate, and liver cancer.”

On July 03, 2020, the network of European HTA agencies, EUnetHTA, published the final report for the Rapid Relative Effectiveness Assessment OTCA24 ‘The 24-hour blood pressure measurement device Mobil-O- Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment.”

On June 18, 2020, the network of European HTA agencies, EUnetHTA, published the final report for the rapid assessment OTCA21 "Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea."